Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (2020) 100648]

Lignende værker

• Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
  af: Oh, Johnathan, et al.
  Udgivet: (2020)
• Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
  af: Ghisoli, Maurizio, et al.
  Udgivet: (2016)
• 1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2
  af: Jay, C., et al.
  Udgivet: (2020)
• Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
  af: David Willoughby, et al.
  Udgivet: (2025-03-01)
• Corrigendum to “Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation” [Gynecol. Oncol. Rep. 22 (2017) 9–12]
  af: Martin, Madhuri, et al.
  Udgivet: (2017)